Improvement in the sensitivity and specificity of the C-peptide immunoassay and studies of larger groups of patients have increased our knowledge of the importance of residual beta-cell function and its metabolic consequences in insulin-treated diabetic patients. During the first five to 10 years after the onset of diabetes mellitus residual beta-cell function is demonstrable in the majority of insulin-treated patients irrespective of the severity of the initial symptoms and only partly dependent on the patient's age at diagnosis. Residual beta-cell function facilitates good control. Stable patients have a higher C-peptide concentration in plasma than unstable ones, but unmeasurable C-peptide is not always associated with poor control. More data are needed before the full significance of an even minimal reserve of beta-cell function is elucidated. It also remains to be shown whether the reduction in beta-cell function in diabetic patients has a qualitative as well as quantitative component.
Skip Nav Destination
Article navigation
Articles|
February 01 1978
Residual Beta-cell Function and Its Metabolic Consequences
Christian Binder, M.D;
Christian Binder, M.D
Hvidøre Hospital
Klampenborg, Denmark
Search for other works by this author on:
Ole K Faber, M.D
Ole K Faber, M.D
Hvidøre Hospital
Klampenborg, Denmark
Search for other works by this author on:
Citation
Christian Binder, Ole K Faber; Residual Beta-cell Function and Its Metabolic Consequences. Diabetes 1 February 1978; 27 (Supplement_1): 226–229. https://doi.org/10.2337/diab.27.1.S226
Download citation file: